GET A QUOTE

TNF-Related Apoptosis Inducing Ligand (TRAIL) ELISA Kit

  • Created on the 29 March, 2017.

BACKGROUND

TNF-related apoptosis-inducing ligand (TRAIL) is composed of 281 amino acid sequence and possesses characteristics similar to a type II transmembrane protein. The C-terminal extracellular domain is found to be conserved and can also be proteolytically cleaved from the cell surface, whereas the N-terminal cytoplasmic domain is not conserved across family members. TRAIL can form homotrimer structures that have the ability to bind three receptor molecules. TRAIL can bind to the death receptors DR4 (TRAIL-RI) and DR5 (TRAIL-RII).

TRAIL is essentially a protein which functions as a ligand in order to induce apoptosis and this process is caspase-8 dependent. Caspase-8 activates downstream effector caspases including procaspase-3, -6, and -7, leading to activation of specific kinases. This whole process leads to transcription of genes which are known to antagonise the death signalling pathway and/or to promote inflammation. TRAIL has also been designated cluster of differentiation 253 (CD253) and tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10) – functioning as mediators of inflammatory responses and immune regulation. The standard product used in this ELISA assay is a recombinant human TRAIL with the molecular mass of 21KDa, it is also expressed from the amino acids ectoderm T95–G28.

INTENDED USE

Human TRAIL ELISA kit is a procedure intended for analysing intended in vitro quantitative levels TNF-related apoptosis-inducing ligand (TRAIL) in human plasma, serum, saliva, cell culture supernatant and cell lysates. This assay has a minimum sensitivity limit of < 1.0 pg/ml.

SENSITIVITY

The minimum detection sensitivity level of TRAIL using this human TRAIL ELISA kit was 1.0 pg/ml. The dynamic assay range for this kit is 15.6 – 1,000 pg/ml.

REFERENCES

  1. Onto better TRAILs for cancer treatment. Cell Death Differ. (2016) 23 (5): 733-47. Review. de Miguel D., et al.
  2. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Adv Exp Med Biol. (2014) 818: 167-80. Review. Fulda S.
  3. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol. (2011) 8 (8): 417-27. Review. Voelkel-Johnson C.
  4. The TRAIL of oncogenes to apoptosis. Biofactors. (2013) 39 (4): 343-54. Review. Oikonomou E. and Pintzas A.
  5. Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system. Int J Mol Sci. (2014) 15 (10): 18557-73. Review. Sarhan D., et al.
  6. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem. (2013) 20 (17): 2254-71. Review. Gasparini C., et al.

ADDITIONAL INFORMATION

  • Full Name: TNF-Related Apoptosis-Inducing Ligand (TRAIL) ELISA Kit
  • Reactivity: Human
  • Sample Type: Saliva, Serum, Cell Culture Supernatant, Plasma, Cell Lysates
  • Sensitivity: < 1.0 pg/ml

OTHER RELATED ELISA KITS

TESTIMONIALS arrow icon

Your secretory IgA ELISA kit gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA kit performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA kits from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA kits. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford